Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Gregor Eisenwort, MD PhD, Alexandra Keller, Michael Willmann, Irina Sadovnik, Greiner Georg, MD PhD, Karoline V. Gleixner, MD, Daniel Ivanov, MSc, Daniela Berger, Gabriele Stefanzl, Christiana Winding, DVM, Gregor Hoermann, Wolfgang R. Sperr, MD, Heinz Sill, MD, Peter Bettelheim, MD, Klaus Geissler, MD, Michael W. Deininger, Thomas Rülicke, Peter Valent, MD

Blood (2019) 134 (Supplement_1): 4223.

https://doi.org/10.1182/blood-2019-122530

Published: 2019

Journal Articles

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

Paul Knoebl, MD, Wolfgang R. Sperr, Peter Schellongowski, MD, Thomas Staudinger, MD, Petra Jilma-Stohlawetz, MD, Peter Quehenberger, MD, Silvia Koder, Ing, Cihan Ay, MD, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 2476.

https://doi.org/10.1182/blood-2018-99-116973

Published: 2018

Journal Articles

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Mathias A. Schneeweiss, Gabriele Stefanzl, Daniela Berger, Gregor Eisenwort, Mohamad Jawhar, Greiner Georg, MD PhD, Gregor Hoermann, Wolfgang R. Sperr, Michel Arock, Andreas Reiter, MD, Peter Valent, Karoline V. Gleixner, MD

Blood (2018) 132 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2018-99-116525

Published: 2018

Journal Articles

Treatment of Patients with Aggressive Systemic Mastocytosis, Mast Cell Leukemia and Mast Cell Sarcoma: A Single Center Experience

Karoline V. Gleixner, MD, Peter Valent, Wolfgang R. Sperr

Blood (2018) 132 (Supplement 1): 1769.

https://doi.org/10.1182/blood-2018-99-116465

Published: 2018

Journal Articles

Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells

Mathias A Schneeweiss, MD, Konstantin Byrgazov, PhD, Chantal B Lucini, PhD, Susanne Herndlhofer, Wolfgang R. Sperr, MD, Thomas Lion, PhD, Gregor Hoermann, Michael W. Deininger, MD PhD, Peter Valent, MD, Karoline V Gleixner, MD

Blood (2016) 128 (22): 5425.

https://doi.org/10.1182/blood.V128.22.5425.5425

Published: 2016

Journal Articles

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

Karoline V Gleixner, MD, Mathias A Schneeweiss, MD, Harald Herrmann, MD, Katharina Blatt, MSc, PhD, Daniela Berger, Gregor Eisenwort, MD PhD, Georg Greiner, MD, Konstantin Byrgazov, PhD, Gregor Hoermann, Marina Konopleva, MD PhD, Islam Waliul, Patrick T Gunning, PhD, Hiroshi Maeda, PhD, Richard Moriggl, PhD, Michael W. Deininger, MD PhD, Thomas Lion, PhD, Michael Andreeff, MD PhD, Peter Valent, MD

Blood (2016) 128 (22): 4241.

https://doi.org/10.1182/blood.V128.22.4241.4241

Published: 2016

Journal Articles

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Mathias A Schneeweiss, MD, Barbara Peter, DVM, Katharina Blatt, MSc,PhD, Daniela Berger, Gabriele Stefanzl, Emir Hadzijusufovic, DVM, Karoline V Gleixner, MD, Peter Valent, MD

Blood (2016) 128 (22): 1965.

https://doi.org/10.1182/blood.V128.22.1965.1965

Published: 2016

Journal Articles

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Wolfgang R. Sperr, MD, Susanne Herndlhofer, Karoline V Gleixner, MD, Michael Girschikofsky, MD, Ansgar Weltermann, MD, Sigrid Machherndl-Spandl, MD, Thamer Sliwa, MD, Rainer Poehnl, MD, Buxhofer-Ausch Veronika, MD, Karin Strecker, MD, Paul Knoebl, MD, Ulrich Jaeger, Klaus Geissler, MD, Michael Kundi, MD, Peter Valent, MD

Blood (2016) 128 (22): 2797.

https://doi.org/10.1182/blood.V128.22.2797.2797

Published: 2016

Journal Articles

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Blood (2016) 128 (22): 396.

https://doi.org/10.1182/blood.V128.22.396.396

Published: 2016

Journal Articles

Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56 bright NK Cells in Acute Myeloid Leukemia

Angelica Cuapio, Dr. MD, Mirte Post, Sabine Cerny-Reiterer, Dr., Markus Osl, Volker Huppert, PhD, Karoline V Gleixner, MD, Susanne Herndlhofer, Wolfgang R Sperr, MD, Peter Valent, MD, Erhard Hofer, Dr.

Blood (2014) 124 (21): 1422.

https://doi.org/10.1182/blood.V124.21.1422.1422

Published: 2014

Journal Articles

The Aurora-Kinase Inhibitor R763/AS703569 Exerts Major Growth-Inhibitory and Apoptosis-Inducing Effects on Neoplastic Mast Cells

Barbara Peter, MVM, Harald Herrmann, MD, Karoline V. Gleixner, MD, Emir Hadzijusufovic, MVM, Sylvia Laffer, PhD, Karina Schuch, Winfried Pickl, MD, Samantha M. Sarno, PhD, Michael Willmann, DVM, Peter Valent, MD

Blood (2010) 116 (21): 3972.

https://doi.org/10.1182/blood.V116.21.3972.3972

Published: 2010

Journal Articles

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Barbara Peter, MVM, Karl J. Aichberger, MD, Karoline V. Gleixner, MD, Veronika Ferenc, MD, Alexander Gruze, Winfried F. Pickl, MD, Michael Willmann, DVM, Peter Valent, MD

Blood (2008) 112 (11): 861.

https://doi.org/10.1182/blood.V112.11.861.861

Published: 2008

Journal Articles

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Renata A. Meyer, MD, Harald Herrmann, MD, Karoline V. Gleixner, MD, Alexander Gruze, Sabine Cerny-Reiterer, MD, Rainer Hubmann, PhD, Medhat Shehata, MD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, MD, Winfried F. Pickl, MD, Junia V. Melo, PhD, Gahininath Y. Bharate, Ulrich Jäger, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2008) 112 (11): 1616.

https://doi.org/10.1182/blood.V112.11.1616.1616

Published: 2008

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Karoline V. Gleixner, MD, Veronika Ferenc, M.D., Alexander Gruze, Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1046.

https://doi.org/10.1182/blood.V110.11.1046.1046

Published: 2007

Journal Articles

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Karoline V. Gleixner, MD, Matthias Mayerhofer, M.D., Uwe Rix, Ph.D., Gregor Hoermann, Alexander Gruze, Maria-Theresa Krauth, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Giulio Superti-Furga, Ph.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1541.

https://doi.org/10.1182/blood.V110.11.1541.1541

Published: 2007

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Michael Kneidinger, MD, Peter Valent, MD, Karoline V. Gleixner, MD, Stefan Florian, MD, Alexandra Boehm, MD, Karoline Sonneck, MD, Margit Weghofer, Christian Lupinek, Susanne Vrtala, MD, Anja Vales, MD, Rudolf Valenta, MD, Giulio Superti-Furga, PhD, Francis Y. Lee, PhD

Blood (2006) 108 (11): 1365.

https://doi.org/10.1182/blood.V108.11.1365.1365

Published: 2006

Journal Articles

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Karoline V. Gleixner, MD, Mayerhofer Matthias, MD, Anja Vales, MD, Alexander Gruze, Michael Kneidinger, MD, Gregor Hoermann, Maria T. Krauth, MD, Rudin Kondo, MD, Karoline Sonneck, MD, Puchit Samorapoompichit, MD, Eva Lackner, MD, Khaled Greish, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Christoph C. Zielinski, MD, Hiroshi Maeda, MD, Peter Valent, MD

Blood (2006) 108 (11): 4323.

https://doi.org/10.1182/blood.V108.11.4323.4323

Published: 2006

Journal Articles

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Michael Kneidinger, MD, Karoline V. Gleixner, md, Rudin Kondo, md, Puchit Samorapoompichit, md, Anja Vales, md, Maria T. Krauth, md, Matthias Mayerhofer, md, Alexander Gruze, Winfried F. Pickl, md, Khaled Greish, Alexandra Boehm, md, Wolfgang R. Sperr, md, Hiroshi Maeda, md, phd, Peter Valent, md

Blood (2006) 108 (11): 1901.

https://doi.org/10.1182/blood.V108.11.1901.1901

Published: 2006

Journal Articles

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, MD, Maria-Theresa Krauth, MD, Alexander Gruze, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 1437.

https://doi.org/10.1182/blood.V108.11.1437.1437

Published: 2006

NARROW

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia (CMML)

Emicizumab for the Treatment of Acquired Hemophilia_A: Lessons Learned from 4 Very Different Cases

The CDK4/6 Inhibitor Palbociclib Exerts Growth-Inhibitory Effects on Neoplastic Mast Cells and Synergizes with Midostaurin in Producing Growth Arrest

Treatment of Patients with Aggressive Systemic Mastocytosis, Mast Cell Leukemia and Mast Cell Sarcoma: A Single Center Experience

Hydroxyurea Induces Growth Inhibition in BCR-ABL1 T315I+ Clones and Synergizes with Ponatinib in Killing TKI-Resistant CML Cells

Combined Targeting of STAT3 and STAT5: A Novel Approach to Overcome Drug Resistance in Ph + Cml

The Multi-Kinase Inhibitor DCC-2618 Inhibits Proliferation and Survival of Neoplastic Mast Cells and Other Cell Types Involved in Systemic Mastocytosis

Intensive Post-Remission Consolidation with G-CSF-Support: Tolerability, Safety, Reduced Hospitalization, and Efficacy of a New Treatment Protocol for AML Patients ≥60 Years

Prognostic Factors and Survival Prediction in 1,088 Patients with Mastocytosis Collected in the Registry of the European Competence Network on Mastocytosis (ECNM Registry)

Maintenance with Histamine and IL-2 Induces a Marked Expansion of Activated CD56 bright NK Cells in Acute Myeloid Leukemia

The Aurora-Kinase Inhibitor R763/AS703569 Exerts Major Growth-Inhibitory and Apoptosis-Inducing Effects on Neoplastic Mast Cells

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Dasatinib (BMS354825) Inhibits IgE-Dependent Activation and Histamine Release in Human Blood Basophils.

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only